Orlando Magic: Report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA

Research output: Contribution to journalArticlepeer-review

Abstract

The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.

Original languageEnglish
Article number612
Journalecancermedicalscience
Volume10
DOIs
Publication statusPublished - Jan 14 2016

Keywords

  • Leukemia
  • Lymphoma
  • Myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Orlando Magic: Report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA'. Together they form a unique fingerprint.

Cite this